XML 108 R75.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Capital Stock (Stock Option, SARs, Restricted Stock and Restricted Share Unit Activity) (Details)
shares in Millions
9 Months Ended
Dec. 31, 2019
$ / shares
shares
Class A Voting Shares | Stock Options and Equity-Settled SARs  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]  
Outstanding at March 31, 2019 (in shares) 8.4
Granted (in shares) 0.0
Options exercised (in shares) 0.0
Forfeited or expired (in shares) (1.1)
Outstanding at December 31, 2019 (in shares) 7.3
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]  
Outstanding at March 31, 2019, weighted average exercise price (in usd per share) | $ / shares $ 26.70
Granted, weighted average exercise price (in usd per share) | $ / shares 0
Options exercised, weighted average exercise price (in usd per share) | $ / shares 0
Forfeited or expired, weighted average exercise price (in usd per share) | $ / shares 29.94
Outstanding at December 31, 2019, weighted average exercise price (in usd per share) | $ / shares $ 26.22
Class A Voting Shares | Restricted Stock and Restricted Share Units (RSUs)  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Outstanding at March 31, 2019 (in shares) 0.1
Granted (in shares) 0.0 [1]
Vested (in shares) (0.1)
Forfeited or expired (in shares) 0.0 [1]
Outstanding at December 31, 2019 (in shares) 0.0 [1]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Outstanding at March 31, 2019, weighted average grant-date fair value (in usd per share) | $ / shares $ 25.68
Granted, weighted average grant date fair value (in usd per share) | $ / shares 11.01
Restricted stock or RSUs vested, weighted average grant-date fair value (in usd per share) | $ / shares 25.93
Forfeited or expired, weighted average grant-date fair value (in usd per share) | $ / shares 18.90
Outstanding at December 31, 2019, weighted average grant-date fair value (in usd per share) | $ / shares $ 14.89
Class B Non-Voting Shares | Stock Options and Equity-Settled SARs  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]  
Outstanding at March 31, 2019 (in shares) 26.2
Granted (in shares) 7.5 [2]
Options exercised (in shares) (0.1)
Forfeited or expired (in shares) (4.2)
Outstanding at December 31, 2019 (in shares) 29.4
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]  
Outstanding at March 31, 2019, weighted average exercise price (in usd per share) | $ / shares $ 20.72
Granted, weighted average exercise price (in usd per share) | $ / shares 12.71
Options exercised, weighted average exercise price (in usd per share) | $ / shares 10.50
Forfeited or expired, weighted average exercise price (in usd per share) | $ / shares 17.82
Outstanding at December 31, 2019, weighted average exercise price (in usd per share) | $ / shares $ 19.06
Class B Non-Voting Shares | Share Appreciation Rights (SARs)  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Granted (in shares) 3.3
Class B Non-Voting Shares | Restricted Stock and Restricted Share Units (RSUs)  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Outstanding at March 31, 2019 (in shares) 1.9
Granted (in shares) 3.1
Vested (in shares) (0.7)
Forfeited or expired (in shares) (0.3)
Outstanding at December 31, 2019 (in shares) 4.0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Outstanding at March 31, 2019, weighted average grant-date fair value (in usd per share) | $ / shares $ 24.24
Granted, weighted average grant date fair value (in usd per share) | $ / shares 12.03
Restricted stock or RSUs vested, weighted average grant-date fair value (in usd per share) | $ / shares 24.22
Forfeited or expired, weighted average grant-date fair value (in usd per share) | $ / shares 20.86
Outstanding at December 31, 2019, weighted average grant-date fair value (in usd per share) | $ / shares $ 15.10
Maximum | Class A Voting Shares | Restricted Stock and Restricted Share Units (RSUs)  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Granted (in shares) 0.1 [1]
Forfeited or expired (in shares) (0.1)
Outstanding at December 31, 2019 (in shares) 0.1
[1]
Represents less than 0.1 million shares.
[2]
During the nine months ended December 31, 2019, the Company granted 3.3 million cash-settled share-appreciation rights ("CSARs"). The CSARs are revalued each reporting period until settlement using a closed-form option pricing model (Black Scholes).